» Authors » Chinn Yi Wong

Chinn Yi Wong

Explore the profile of Chinn Yi Wong including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 526
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Edeling M, Earnest L, Montoya J, Yap A, Mumford J, Roberts J, et al.
Biotechnol Bioeng . 2025 Feb; PMID: 39936889
The devastating global toll precipitated by the SARS CoV-2 outbreak and the profound impact of vaccines in stemming that outbreak has established the need for molecular platforms capable of rapidly...
2.
Al-Wassiti H, Fabb S, Grimley S, Kochappan R, Ho J, Wong C, et al.
Mol Ther Methods Clin Dev . 2024 Dec; 32(4):101380. PMID: 39687732
We investigated mRNA vaccines encoding a membrane-anchored receptor-binding domain (RBD), each a fusion of a variant RBD, the transmembrane (TM) and cytoplasmic tail fragments of the severe acute respiratory syndrome...
3.
Premachandre C, Quah P, Tran B, Vincan E, Deliyannis G, Wong C, et al.
Vet Microbiol . 2024 Dec; 300:110340. PMID: 39675119
In vitro three-dimensional organoid models simulate key aspects of the structure and function of in vivo organs and have been used to study physiology, host-pathogen interactions, pathogenesis and pharmacodynamics. Although...
4.
Jia X, Crawford J, Gebregzabher D, Monson E, Mettelman R, Wan Y, et al.
Cell . 2024 Aug; 187(17):4586-4604.e20. PMID: 39137778
Respiratory infections cause significant morbidity and mortality, yet it is unclear why some individuals succumb to severe disease. In patients hospitalized with avian A(H7N9) influenza, we investigated early drivers underpinning...
5.
Nolan T, Deliyannis G, Griffith M, Braat S, Allen L, Audsley J, et al.
EBioMedicine . 2023 Nov; 98:104878. PMID: 38016322
Background: SARS-CoV-2 booster vaccination should ideally enhance protection against variants and minimise immune imprinting. This Phase I trial evaluated two vaccines targeting SARS-CoV-2 beta-variant receptor-binding domain (RBD): a recombinant dimeric...
6.
Collett S, Earnest L, Montoya J, Edeling M, Yap A, Wong C, et al.
Front Microbiol . 2023 Jun; 14:1065609. PMID: 37350788
The development of virus-like particle (VLP) based vaccines for human papillomavirus, hepatitis B and hepatitis E viruses represented a breakthrough in vaccine development. However, for dengue and COVID-19, technical complications,...
7.
Deliyannis G, Gherardin N, Wong C, Grimley S, Cooney J, Redmond S, et al.
EBioMedicine . 2023 May; 92:104574. PMID: 37148585
Background: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability...
8.
Occhinegro A, Wong C, Chua B, Jackson D, McKinley M, McAllen R, et al.
Brain Behav Immun . 2021 Aug; 97:371-375. PMID: 34333113
The splanchnic anti-inflammatory pathway, the efferent arm of the endogenous inflammatory reflex, has been shown to suppress the acute inflammatory response of rats to systemic lipopolysaccharide (LPS). Here we show...
9.
Selva K, van de Sandt C, Lemke M, Lee C, Shoffner S, Chua B, et al.
Nat Commun . 2021 Apr; 12(1):2037. PMID: 33795692
The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, induced by circulating human coronaviruses (hCoVs), is needed to...
10.
Rowntree L, Chua B, Nicholson S, Koutsakos M, Hensen L, Douros C, et al.
Clin Transl Immunology . 2021 Mar; 10(3):e1258. PMID: 33680466
Objectives: As the world transitions into a new era of the COVID-19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify...